Cargando…
Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study
BACKGROUND: Increased mineralocorticoid activity is one of the plausible causes of chronic central serous chorioretinopathy (CSCR) and mineralocorticoid inhibitors such as eplerenone have been investigated as its potential therapy. This study investigates the short-term safety and efficacy of oral e...
Autores principales: | Moein, Hamid-Reza, Bierman, Lauren W., Novais, Eduardo A., Moreira-Neto, Carlos, Baumal, Caroline R., Rogers, Adam, Duker, Jay S., Witkin, André J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734298/ https://www.ncbi.nlm.nih.gov/pubmed/31516734 http://dx.doi.org/10.1186/s40942-019-0190-y |
Ejemplares similares
-
Eplerenone Treatment in Chronic Central Serous Chorioretinopathy
por: Iqbal, Faisal, et al.
Publicado: (2021) -
Real-world practice patterns of eplerenone use for central serous chorioretinopathy
por: Venkatesh, Ramesh, et al.
Publicado: (2023) -
Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature
por: Chatziralli, Irini, et al.
Publicado: (2018) -
Lack of efficacy of eplerenone for treatment of active central serous chorioretinopathy
por: Sadda, Srinivas R.
Publicado: (2020) -
Bilateral bullous central serous chorioretinopathy treated with PDT and eplerenone
por: Anderson, William J., et al.
Publicado: (2022)